Clotting factor concentrates (CFC) or bypassing agents (BPA) + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia a

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 22 Dec 2022: Trial registered, NCT05662319
  2. 1 Feb 2023: Trial started, NCT05662319
  3. 16 Dec 2025: Trial registered, NCT07285460
  4. 18 Dec 2025: Trial started, NCT07285460

The trials

NCT05662319: A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

State
Under way
Phase
Phase 3
People
91 taking part
Started
1 Feb 2023
Primary completion
25 Mar 2027
Arms
All participants
Results
None posted
  1. 22 Dec 2022: Trial registered
  2. 1 Feb 2023: Trial started

NCT07285460: A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

State
Under way
Phase
Phase 3
People
85 planned
Started
18 Dec 2025
Primary completion
4 Aug 2029
Arms
Fitusiran-naïve arm, EFC15647 roll-over arm
Results
None posted
  1. 16 Dec 2025: Trial registered
  2. 18 Dec 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.